IGEM Therapeutics appoints Dr David Chiswell

IGEM Therapeutics, an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, announces that Dr David Chiswell will be joining IGEM as a Non-Executive Chairman effective immediately.

Having recently stepped down from his position as Kymab’s CEO, Dr Chiswell brings more than 30 years’ experience in the biotechnology industry to IGEM’s Board. Kymab announced their Dr Chiswell’s replacement yesterday in Simon Sturge, who joins from Merck. 

Dr Chiswell co-founded Cambridge Antibody Technology (CAT) in 1990 where he served as CEO for six years, overseeing the company’s float on both the London Stock Exchange and Nasdaq in April 1997 and June 2001, respectively. Additionally, Dr Chiswell is a past chairman of the UK BioIndustry Association (BIA) and his contributions to the field were recognised in 2006 when he was awarded an OBE for services to the biotechnology industry.

Commenting on the appointment, Dr Tim Wilson, Chief Executive Officer of IGEM, said:

“We are thrilled to have Dr Chiswell joining our Board of Directors. His in-depth knowledge of therapeutic antibody discovery and development as well as his extensive experience leading the growth of early-stage biotechnology companies will make him an invaluable member of our team. I look forward to working with him and the rest of our Board. Additionally, I would like to thank Peter for Chairing the company with distinction over the past two years.”

Dr Chiswell, added:

“I am delighted to be joining IGEM Therapeutics as Non-Executive Chairman. IGEM’s management team has a strong vision for the future and I look forward to working with them to evolve it further as they develop their exciting pipeline of immunoglobulin E antibodies to address a number of significantly unmet areas in oncology.”